Antengene Appoints Dr. Bing Hou as Chief Scientific Officer to Drive Next-Generation Drug Discovery and Innovation

Antengene Appoints Dr. Bing Hou as Chief Scientific Officer – Strategic Move to Accelerate R&D and Pipeline Innovation

Key Highlights

Appointment of Chief Scientific Officer (CSO): Antengene Corporation Limited has appointed Dr. Bing Hou as its new CSO, marking a significant step in its leadership team and R&D strategy.
Leadership and Innovation Focus: Dr. Hou will oversee Drug Discovery, Translational Medicine, and Chemistry, Manufacturing and Controls (CMC), with the objective of deepening Antengene’s research capabilities and advancing its pipeline of next-generation therapeutics.
Proprietary Platform Success: Dr. Hou has played a pivotal role in developing Antengene’s proprietary AnTenGager^® T-cell engager (TCE) 2.0 platform, which has broad applications in autoimmune diseases, solid tumors, and hematological malignancies.
Strategic Global Licensing Agreement: The company recently entered into a global license agreement with UCB for ATG-201 (a CD19 x CD3 TCE developed from the AnTenGager^® platform) for B cell-related autoimmune diseases – highlighting Antengene’s proprietary discovery capabilities and the commercial potential of its pipeline.
Innovative Pipeline Advancements: Key assets under Dr. Hou’s leadership include:
- ATG-125: A B7-H3 x PD-L1 bispecific antibody-drug conjugate (ADC) synergizing ADC and immuno-oncology mechanisms.
- ATG-207: A globally first-in-class αCD3-TGF-β bifunctional fusion protein targeting T cell-driven autoimmune diseases.
Dr. Hou’s Credentials: Dr. Hou holds a Ph.D. in Biomedicine from the University of Leeds, has published in leading journals (Nature, Science Advances, Cancer Research), and filed over 40 patent applications. He has been instrumental in advancing first-in-class or best-in-class drug candidates through clinical development.
Leadership Track Record: Since joining Antengene in 2019, Dr. Hou has built and led a high-caliber discovery organization, advancing internally discovered programs into clinical development and establishing proprietary platforms for future innovation.

Implications for Shareholders and Potential Price Sensitivity

Strengthening of R&D Leadership: The formal appointment of Dr. Hou as CSO signals Antengene’s commitment to innovation-driven growth. His track record, both scientifically and in leading teams, could accelerate the development and commercialization of novel therapeutics, enhancing long-term shareholder value.
Expansion of Pipeline and Strategic Partnerships: The successful global licensing of ATG-201 to UCB validates the company’s proprietary technology and opens the door for future partnerships, licensing deals, and revenue streams.
Potential for Share Price Impact: The combination of R&D strength, strategic alliances, and a differentiated pipeline positions Antengene for potential share price appreciation, especially as new assets advance through clinical development and reach commercialization milestones.
Leadership Continuity: Dr. Hou’s promotion from within ensures continuity and leverages his deep institutional knowledge, which could minimize execution risks associated with R&D and innovation.

Management Statements

Dr. Jay Mei, Founder, Chairman, and CEO of Antengene, highlighted Dr. Hou’s significant contributions in shaping the company’s scientific strategy and internal research capabilities. Under Dr. Hou’s leadership, Antengene has built and advanced the AnTenGager^® TCE 2.0 platform and secured a high-impact global license agreement for ATG-201 with UCB. Dr. Mei emphasized that Dr. Hou’s continued leadership will be crucial as the company enters its next stage of growth, expanding its innovative pipeline and bringing transformative therapies to patients worldwide.

Dr. Hou expressed his honor and excitement in stepping into the CSO role. He reiterated Antengene’s focus on advancing programs with the potential to address significant unmet medical needs and leveraging the company’s differentiated science and platform capabilities to develop a robust pipeline of innovative medicines.

Company Background & Board Composition

Antengene Corporation Limited is a global biopharmaceutical company committed to innovative drug discovery and development, particularly in oncology and autoimmune diseases.
As of May 20, 2026, the Board comprises Dr. Jay Mei and Mr. Donald Andrew Lung as executive Directors; and Ms. Jing Qian, Mr. Sheng Tang, and Dr. Rafael Fonseca as independent non-executive Directors.

Conclusion

The appointment of Dr. Bing Hou as Chief Scientific Officer is a strategically significant move for Antengene, reinforcing its innovation-driven R&D model, strengthening its leadership team, and supporting the advancement of a differentiated and commercially promising pipeline. The recent global licensing deal with UCB and the continued development of proprietary platforms could be materially positive for the company’s growth prospects and share value.

Disclaimer

This article is for informational purposes only and does not constitute investment advice or an offer to buy or sell any securities. Investors should conduct their own due diligence and consult with professional advisors before making investment decisions.

Antengene 委任侯兵博士為首席科學官——加速研發及管線創新之重大舉措

重點摘要

首席科學官任命：Antengene Corporation Limited（德琪醫藥）正式委任侯兵博士為首席科學官（CSO），這是公司領導團隊及研發戰略上的重要一步。
領導與創新重點：侯博士將全面負責藥物發現、轉化醫學及化學、製造與控制（CMC），以深化公司科研能力及推動下一代創新治療產品線的發展。
專有平台成就：侯博士主導開發了公司專有的 AnTenGager^® T細胞連接器（TCE）2.0平台，該平台具有在自身免疫疾病、實體腫瘤及血液腫瘤領域的廣泛應用價值。
全球授權協議：公司最近與UCB達成全球授權協議，授權ATG-201（由AnTenGager^®平台開發的CD19 x CD3 TCE）用於B細胞相關自身免疫疾病——突顯Antengene專有技術和管線的商業潛力。
創新產品線推進：在侯博士領導下，主要產品包括：
- ATG-125：一種B7-H3 x PD-L1雙特異性抗體偶聯藥物（ADC），結合ADC及免疫腫瘤學機制。
- ATG-207：全球首創αCD3-TGF-β雙功能融合蛋白，針對T細胞驅動的自身免疫疾病。
侯博士資歷：侯博士擁有英國利茲大學生物醫學博士學位，在《Nature》、《Science Advances》、《Cancer Research》等頂級期刊發表多篇高影響力論文，並申請超過40項新型治療專利。
領導經驗：自2019年加入Antengene以來，侯博士建立並領導了高水平的發現團隊，推動公司自主研發項目進入臨床開發，並建立了支撐未來創新計劃的專有平台。

對股東及潛在股價敏感事項的影響

加強研發領導力：正式任命侯博士為CSO，反映公司對創新驅動增長的堅定承諾。他在科研和團隊領導方面的成就，或將加快創新藥物的開發與商業化，有望提升股東長遠價值。
管線擴展及戰略合作：ATG-201成功授權UCB，驗證公司專利技術，為未來更多合作與收入來源鋪路。
股價潛在影響：公司在研發實力、戰略聯盟及差異化產品線上的發展，有望推動股價隨臨床及商業化里程碑而上升。
領導層持續穩定：侯博士內部晉升確保研發及創新戰略執行連續性，降低項目實施風險。

管理層言論

創始人、董事長兼行政總裁梅建明博士指出，侯博士對公司科研戰略及內部研究能力的發展作出了重大貢獻。在其領導下，Antengene成功構建並推進 AnTenGager^® TCE 2.0平台，並與UCB達成高影響力的全球授權協議。他強調，隨公司邁入新發展階段，侯博士的持續領導將推動公司創新產品線擴展，為全球患者帶來突破性治療。

侯博士表示，對於獲任CSO深感榮幸和興奮。未來將繼續聚焦於具有重大未被滿足醫療需求的項目，並以差異化科研及平台能力，轉化為創新藥物產品線。

公司簡介及董事會組成

Antengene Corporation Limited（德琪醫藥）是一家專注於腫瘤及自身免疫疾病創新藥物研發的全球生物醫藥公司。
截至2026年5月20日，董事會成員包括執行董事梅建明博士、Donald Andrew Lung先生，以及獨立非執行董事錢靜女士、唐晟先生和Rafael Fonseca博士。

總結

委任侯兵博士為首席科學官是Antengene在強化創新研發模式、領導團隊及推動差異化產品線發展上的關鍵舉措。與UCB的全球授權協議及專有平台的持續開發，對公司增長前景和股價有潛在正面影響。

免責聲明

本文僅供參考，並不構成投資建議或購買／出售任何證券的邀請。投資者應自行進行盡職調查，並諮詢專業顧問後作出投資決定。